Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy : a real-world registry experience
© 2023. The Author(s)..
BACKGROUND: Acute myeloid leukaemia (AML) is treated with intensive induction chemotherapy (IT) in medically fit patients. In general, obesity was identified as a risk factor for all-cause mortality, and there is an ongoing debate on its impact on outcome and optimal dosing strategy in obese AML patients.
METHODS: We conducted a registry study screening 7632 patients and assessed the impact of obesity in 1677 equally IT treated, newly diagnosed AML patients on the outcome (OS, EFS, CR1), comorbidities, toxicities and used dosing strategies.
RESULTS: Obese patients (BMI ≥ 30) displayed a significant inferior median OS (29.44 vs. 47.94 months, P = 0.015) and CR1 rate (78.7% vs. 84.3%, P = 0.015) without differences in median EFS (7.8 vs. 9.89 months, P = 0.3) compared to non-obese patients (BMI < 30). The effect was predominantly observed in older (≥60 years) patients. Obesity was identified as an independent risk factor for death, and obese patients demonstrated higher rates of cardiovascular or metabolic comorbidities. No differences for OS, EFS, CR1 or treatment-related toxicities were observed by stratification according to used dosing strategy or dose reduction.
CONCLUSIONS: In conclusion, this study identifies obesity as an independent risk factor for worse OS in older AML patients undergoing curative IT most likely due to obesity-related comorbidities and not to dosing strategy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:129 |
|---|---|
| Enthalten in: |
British journal of cancer - 129(2023), 7 vom: 04. Okt., Seite 1126-1133 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 03.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1038/s41416-023-02362-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360417981 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360417981 | ||
| 003 | DE-627 | ||
| 005 | 20231226082953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41416-023-02362-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360417981 | ||
| 035 | |a (NLM)37542108 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Enßle, Julius C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy |b a real-world registry experience |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: Acute myeloid leukaemia (AML) is treated with intensive induction chemotherapy (IT) in medically fit patients. In general, obesity was identified as a risk factor for all-cause mortality, and there is an ongoing debate on its impact on outcome and optimal dosing strategy in obese AML patients | ||
| 520 | |a METHODS: We conducted a registry study screening 7632 patients and assessed the impact of obesity in 1677 equally IT treated, newly diagnosed AML patients on the outcome (OS, EFS, CR1), comorbidities, toxicities and used dosing strategies | ||
| 520 | |a RESULTS: Obese patients (BMI ≥ 30) displayed a significant inferior median OS (29.44 vs. 47.94 months, P = 0.015) and CR1 rate (78.7% vs. 84.3%, P = 0.015) without differences in median EFS (7.8 vs. 9.89 months, P = 0.3) compared to non-obese patients (BMI < 30). The effect was predominantly observed in older (≥60 years) patients. Obesity was identified as an independent risk factor for death, and obese patients demonstrated higher rates of cardiovascular or metabolic comorbidities. No differences for OS, EFS, CR1 or treatment-related toxicities were observed by stratification according to used dosing strategy or dose reduction | ||
| 520 | |a CONCLUSIONS: In conclusion, this study identifies obesity as an independent risk factor for worse OS in older AML patients undergoing curative IT most likely due to obesity-related comorbidities and not to dosing strategy | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Wolf, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Scheich, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Kramer, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Ruhnke, Leo |e verfasserin |4 aut | |
| 700 | 1 | |a Schliemann, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Mikesch, Jan-Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Krause, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Sauer, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Hanoun, Maher |e verfasserin |4 aut | |
| 700 | 1 | |a Reinhardt, Hans Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Kraus, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Kaufmann, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Hänel, Mathias |e verfasserin |4 aut | |
| 700 | 1 | |a Fransecky, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Burchert, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Neubauer, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Crysandt, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Jost, Edgar |e verfasserin |4 aut | |
| 700 | 1 | |a Niemann, Dirk |e verfasserin |4 aut | |
| 700 | 1 | |a Schäfer-Eckart, Kerstin |e verfasserin |4 aut | |
| 700 | 1 | |a Held, Gerhard |e verfasserin |4 aut | |
| 700 | 1 | |a Kaiser, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Wass, Maxi |e verfasserin |4 aut | |
| 700 | 1 | |a Schaich, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |e verfasserin |4 aut | |
| 700 | 1 | |a Platzbecker, Uwe |e verfasserin |4 aut | |
| 700 | 1 | |a Baldus, Claudia D |e verfasserin |4 aut | |
| 700 | 1 | |a Bornhäuser, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Röllig, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Serve, Hubert |e verfasserin |4 aut | |
| 700 | 0 | |a Study Alliance Leukemia (SAL) |e verfasserin |4 aut | |
| 700 | 1 | |a Steffen, Björn |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d 1947 |g 129(2023), 7 vom: 04. Okt., Seite 1126-1133 |w (DE-627)NLM000027537 |x 1532-1827 |7 nnns |
| 773 | 1 | 8 | |g volume:129 |g year:2023 |g number:7 |g day:04 |g month:10 |g pages:1126-1133 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41416-023-02362-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 129 |j 2023 |e 7 |b 04 |c 10 |h 1126-1133 | ||